BI launches Combivent Respimat

Propellant-free inhaler requires one inhalation per dose

RIDGEFIELD, Conn. — Boehringer Ingelheim Pharmaceuticals has launched a drug for treating chronic obstructive pulmonary disease, the company said Tuesday.

BI Pharmaceuticals announced the launch of Combivent Respimat (ipratropium bromide and albuterol), calling it a propellant-free inhaler that uses a slow-moving mist to deliver the same active ingredients as the Combivent metered dose inhaler, requiring one inhalation per dose, compared with Combivent MDI's two inhalations.

"Combivent Respimat is a testament to our company's commitment to developing advancements for peole living with respiratory disease," BI Pharmaceuticals VP clinical development and medical affairs Tunde Otulana said. "We are continuing to examine the potential of several late-stage investigational compounds also delivered by the Respimat inhaler."


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter. 

Login or Register to post a comment.